ABU DHABI: Abu Dhabi Stem Cells Center (ADSCC), a leading research institute in Abu Dhabi, has signed a Memorandum of Understanding with Beckman Coulter Diagnostics to offer its facility as a center of training and knowledge development in blood cancer diagnosis.
As part of the agreement, ADSCC’s flow cytometry facility will serve as a Center of Excellence in the UAE and region, aiding in the research and development of targeted stem cell therapies while leveraging the diagnostic technology and know-how offered by Beckman Coulter. Flow cytometry is a laboratory method and technology that rapidly detects, identifies, and counts specific cells. This method can also identify particular components within cells, making it indispensable to immunology and the diagnosis and treatment of blood cell cancers (e.g. leukemias and lymphomas).
Speaking to the significance of the partnership, Dr Fatema Al Kaabi, Director of the Abu Dhabi Bone Marrow Transplant Program, said: “As a Center of Excellence in partnership with Beckman Coulter, we will be the first in the country and region to standardize and manage the flow cytometry process which is crucial to effectively diagnosing blood cancers. We are highly encouraged by this agreement as it stands as a testament to the efforts underway to strengthen stem cell therapy in Abu Dhabi, establishing the Emirate as a hub for medical research and innovation.”
Remarking on the partnership’s potential, Dr Yendry Ventura Carmenate, Specialist in Immunology, General Manager of ADSCC, said: “This marks the beginning of a very promising collaboration that will establish the Abu Dhabi Stem Cells Center as a key point of referral for the diagnosis and treatment of hematological cancers such as myeloma, lymphoma, and certain forms of leukemia. Working with Beckman Coulter, a global leader in biomedical testing, allows us to combine our world-class facility with their pioneering technology to maximize efficiency and create a new standard for stem cell therapy.”
Beckman Coulter is a global manufacturer of products that simplify, automate, and innovate complex biomedical testing. Through this MoU, the company will provide its own proprietary flow cytometry platform to the ADSCC facility, with the larger goal of making the flow cytometry process routine for both novice and expert users and promote standardization.
Commenting on the newly-announced partnership, Albert Alterjman, General Manager of Beckman Coulter Life Sciences, said: “At Beckman Coulter, we are committed to driving innovation in everything we do. To establish a Center of Excellence at ADSCC, we seek to shape flow cytometry technology in a way that fits seamlessly into their laboratory’s workflow and provides an optimal user experience. We are excited to be working together to deliver a high level of expertise, innovation, and quality assurance in the diagnostic process.”
ADSCC was founded in 2019 with the primary objective of meeting growing domestic and regional demand for advanced medical services and the most innovative treatments in the country. As a leader in stem cell therapy in the UAE and region, ADSCC recently succeeded in its first experiment to locally manufacture CAR T-Cells in a laboratory and is close to starting clinical trials to prove the safety and effectiveness of CAR T-Cell therapy in treating hematologic cancers.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
